Vincristine-induced peripheral neurotoxicity: A prospective cohort

References

• Gidding CE, Kellie SJ, Kamps WA, et al. Vincristine revisited. Crit Rev Oncol Hematol. 1999;29(3):267–287. doi:10.1016/S1040-8428(98)00023-7.
   PubMed Web of Science ®Google Scholar
• van de Velde ME, Kaspers GL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in children with cancer: a systematic review. Crit Rev Oncol Hematol. 2017;114:114–130. doi:10.1016/j.critrevonc.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Lanzkowsky P, Lipton JM, Fish JD. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. Amsterdam: Academic Press; 2016.
   Google Scholar
• Jain P, Gulati S, Seth R, et al. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol. 2014;29(7):932–937. doi:10.1177/0883073813491829.
   PubMed Web of Science ®Google Scholar
• Purser MJ, Johnston DL, McMillan HJ. Chemotherapy-induced peripheral neuropathy among paediatric oncology patients. Can J Neurol Sci. 2014;41(4):442–447. doi:10.1017/S0317167100018461.
   PubMed Web of Science ®Google Scholar
• Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2008;50(4):769–771. doi:10.1002/pbc.21435.
   PubMed Web of Science ®Google Scholar
• Gilchrist LS, Tanner L, Hooke MC. Measuring chemotherapy-induced peripheral neuropathy in children: development of the Ped-mTNS and pilot study results. Rehabil Oncol. 2009;27(3):7–15. doi:10.1097/01893697-200927030-00002.
   Google Scholar
• Yildiz FG, Temucin ÇM. Vincristine-induced neurotoxicity: electrophysiological features in children. Neurol Res. 2016;38(2):124–129. doi:10.1080/01616412.2016.1139321.
   PubMed Web of Science ®Google Scholar
• Lavoie Smith EM, Li L, Chiang C, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst. 2015;20(1):37–46. doi:10.1111/jns.12114.
   PubMed Web of Science ®Google Scholar
• Gilchrist LS, Tanner L. The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer. 2013;21(3):847–856. doi:10.1007/s00520-012-1591-8.
   PubMed Web of Science ®Google Scholar
• Arzanian MT, Mehdizadeh M, Zamani GR. Vincristine induced neurotoxicity: study of 75 cases. Iran J Child Neurol. 2009;3(2):39–44. doi:10.22037/ijcn.v3i2.1271.
   Google Scholar
• Courtemanche H, Magot A, Ollivier Y, et al. Vincristine-induced neuropathy: atypical electrophysiological patterns in children. Muscle Nerve. 2015;52(6):981–985. doi:10.1002/mus.24647.
   PubMed Web of Science ®Google Scholar
• Plasschaert SLA, Groninger E, Boezen M, et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther. 2004;76(3):220–229. doi:10.1016/j.clpt.2004.05.007.
   PubMed Web of Science ®Google Scholar
• Lombardi AJ, Sutton ME, Tiao GM, et al. Vincristine-associated neurological morbidity in the treatment of hepatoblastoma. J Pediatr Hematol Oncol. 2015;37(4):e258–e263. doi:10.1097/MPH.0000000000000321.
   PubMed Web of Science ®Google Scholar
• Sabarre CL, Rassekh SR, Zwicker JG. Vincristine and fine motor function of children with acute lymphoblastic leukemia. Can J Occup Ther. 2014;81(4):256–264. doi:10.1177/0008417414539926.
   PubMed Web of Science ®Google Scholar
• Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815–823. doi:10.1001/jama.2015.0894.
   PubMed Web of Science ®Google Scholar
• Ceppi F, Langlois-Pelletier C, Gagné V, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(8):1105–1116. doi:10.2217/pgs.14.68.
   PubMed Web of Science ®Google Scholar
• Guilhaumou R, Solas C, Bourgarel-Rey V, et al. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol. 2011;68(6):1633–1638. doi:10.1007/s00280-011-1745-2.
   PubMed Web of Science ®Google Scholar
• Toopchizadeh V, Barzegar M, Rezamand A, et al. Electrophysiological consequences of vincristine contained chemotherapy in children: a cohort study. J Pediatr Neurol. 2009;7(4):351–356. doi:10.3233/JPN-2009-0333.
   Google Scholar
• Reinders-Messelink HA, Van Weerden TW, Fock JM, et al. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. Eur J Paediatr Neurol. 2000;4(5):225–233. doi:10.1053/ejpn.1999.0310.
   PubMedGoogle Scholar
• Aplenc R, Glatfelter W, Han P, et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2003;122(2):240–244. doi:10.1046/j.1365-2141.2003.04430.x.
   PubMed Web of Science ®Google Scholar
• Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361–367. doi:10.1002/pbc.22845.
   PubMed Web of Science ®Google Scholar
• Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007;109(10):4151–4157. doi:10.1182/blood-2006-10-054528.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, et al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016;17(7):731–741. doi:10.2217/pgs-2016-0001.
   PubMed Web of Science ®Google Scholar
• Bruininks RH, Bruininks BD. Bruininks-Oseretsky Test of Motor Proficiency. 2nd ed. Minneapolis, MN: Pearson Assessments; 2005. doi:10.1037/t14991-000.
   Google Scholar
• Clarkson HM. Musculoskeletal Assessment: Joint Motion and Muscle Testing. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
   Google Scholar
• Williams EN, Carroll SG, Reddihough DS, et al. Investigation of the timed “up & go” test in children. Dev Med Child Neurol. 2005;47(8):518–524. doi:10.1017/S0012162205001027.
   PubMed Web of Science ®Google Scholar
• Nicolini-Panisson RD, Donadio M. Normative values for the timed “up and go” test in children and adolescents and validation for individuals with Down syndrome. Dev Med Child Neurol. 2014;56(5):490–497. doi:10.1111/dmcn.12290.
   PubMed Web of Science ®Google Scholar
• Smith EML, Beck SL, Beck SL, et al. The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008;35(1):96–102. doi:10.1188/08.ONF.96-102.
   PubMed Web of Science ®Google Scholar
• Lavoie Smith EM, Li L, Hutchinson RJ, et al. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 2013;36(5):E49–E60. doi:10.1097/NCC.0b013e318299ad23.
   PubMed Web of Science ®Google Scholar
• de Graaf SS, Bloemhof H, Vendrig DE, et al. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1995;24(4):235–240. doi:10.1002/mpo.2950240405.
   PubMedGoogle Scholar
• Crom WR, de Graaf SS, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. 1994;125(4):642–649. doi:10.1016/S0022-3476(94)70027-3.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics. 2016;26(2):100–102. doi:10.1097/FPC.0000000000000191.
   PubMed Web of Science ®Google Scholar
• Gilchrist LS, Tanner LR, Ness KK. Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer. Pediatr Blood Cancer. 2017;64(1):180–187. doi:10.1002/pbc.26204.
   PubMed Web of Science ®Google Scholar
• Gilchrist LS, Tanner LR. Short-term recovery of balance control: association with chemotherapy-induced peripheral neuropathy in pediatric oncology. Pediatr Phys Ther. 2018;30(2):119–124. doi:10.1097/PEP.0000000000000484.
   PubMed Web of Science ®Google Scholar
• Tay CG, Lee VWM, Ong LC, et al. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2017;64(8):e26471. doi:10.1002/pbc.26471.
   Web of Science ®Google Scholar
• Ramchandren S, Leonard M, Mody RJ, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst. 2009;14(3):184–189. doi:10.1111/j.1529-8027.2009.00230.x.
   PubMed Web of Science ®Google Scholar
• Ja'afer FMH, Hamdan FB, Mohammed FH. Vincristine-induced neuropathy in rat: electrophysiological and histological study. Exp Brain Res. 2006;173(2):334–345. doi:10.1007/s00221-006-0499-2.
   PubMed Web of Science ®Google Scholar
• Smolik S, Arland L, Hensley MA, et al. Assessment tools for peripheral neuropathy in pediatric oncology: a systematic review from the children's oncology group. J Pediatr Oncol Nurs. 2018;35(4):267–275. doi:10.1177/1043454218762705.
   PubMed Web of Science ®Google Scholar
• Gilchrist LS, Marais L, Tanner L. Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer. 2014;22(2):359–366. doi:10.1007/s00520-013-1981-6.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez G, Sereno M, Miralles A, et al. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010;12(2):81–91. doi:10.1007/S12094-010-0474-z.
   PubMed Web of Science ®Google Scholar
• Anghelescu DL, Faughnan LG, Jeha S, et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(7):1147–1153. doi:10.1002/pbc.23039.
   PubMed Web of Science ®Google Scholar
• Gohar SF, Marchese V, Comito M. Physician referral frequency for physical therapy in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2010;27(3):179–187. doi:10.3109/08880010903580209.
   PubMed Web of Science ®Google Scholar
• Calhoun EA, Chang CH, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist. 2001;6(5):441–445. doi:10.1634/theoncologist.6-5-441.
   PubMed Web of Science ®Google Scholar
• Tai EW, Ward KC, Bonaventure A, et al. Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: findings from the CONCORD-2 study. Cancer. 2017;123 (Suppl 24):5178–5189. doi:10.1002/cncr.30899.
   PubMedGoogle Scholar
• Frost BM, Lönnerholm G, Koopmans P, et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr. 2007;92(5):551–557. doi:10.1111/j.1651-2227.2003.tb02505.x.
   Google Scholar
• Butturini A, Dorey F, Gaynon P, et al. Obesity and body weight independently predict relapse and survival in preadolescents and teenagers with acute lymphoblastic leukemia (ALL). A retrospective analysis of five children cancer group (CCG) studies. Blood. 2004;104(11):992–992.
   Web of Science ®Google Scholar
• Lew G, Yanofsky R, Winick N, et al. Intensive vincristine is not feasible in intermediate-risk relapse of childhood acute lymphoblastic leukemia (ALL): a report from children's oncology group study AALL0433. Pediatr Blood Cancer. 2011;56(6):919.
   Web of Science ®Google Scholar